M&A activity – new inflammatory disease targets fuelling investment interest

A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth.

MoonLake Immunotherapies (Nasdaq: MLTX) is not the only company to refocus its energy and resources on targeting inflammatory disease using its novel nanobody sonelokimab. In the last three months, numerous strategic alliances have been announced that target a variety of chronic inflammatory-driven diseases including arthritis (A), chronic obstructive pulmonary diseases (COPD) and inflammatory bowel disease (IBD). The global market for inflammatory diseases was estimated to be worth around $104 billion in 2022 and is forecast to reach $234 billion by 2032 delivering a compound average growth rate (CAGR) 2023-2032 of 8.4%. Growth is expected to be driven by an increase in the prevalence and incidence of chronic inflammatory diseases and therapeutic advances in the development of novel biologics.

Figure 1: Anti-inflammatory Drug market, 2021-2032